← Eichor
Study identifier: NCT06819449 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients

Condition: Leprosy · Mycobacterium Leprae Infection  ·  Sponsor: South Valley University

PhaseNA
Planned participants50
Who can joinAll sexes, 5 Years to 60 Years
Healthy volunteersNo

About this study

Mycobacterium leprae is a slow-growing bacillus that causes leprosy. the infection may take two to ten years to incubate. While the exact mechanism of infection transmission is unknown, direct bacillus absorption through the nasal or respiratory mucosa and aerosolized nasal secretions are the most common theories. The bacteria is subsequently transported by the bloodstream to the peripheral nerves, where it can result in tissue damage from painless burns and ulcers as well as irreparable nerve damage that results in a loss of protective feeling.

This description comes directly from the study's public registry record.

Talk to the study team

Lydia Atef Nassief, MSc  ·  +201289416276  ·  lydiaatef67@gmail.com

Eisa Mohammed Hegazy, Assist. Prof  ·  +201094337795  ·  eisa_mohamed4152@med.svu.edu.eg

Always discuss trial participation with your own doctor first.

Locations (1)

Qina University hospital, South Valley University HospitalQina, EgyptRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06819449